These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 7504754)

  • 1. [Clinical evaluation of a lung cancer-associated protein antigen, cytokeratin 19 fragment: I. Radioimmunoassay and its fundamental character for clinical laboratory measurement].
    Kubo N; Gang Y; Okuno M; Sakurabayashi I
    Rinsho Byori; 1993 Oct; 41(10):1173-8. PubMed ID: 7504754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical evaluation of a lung cancer-associated protein antigen, cytokeratin 19 fragment: II. Radioimmunoassay and effect of aging and smoking over serum level of normal individuals].
    Kubo N; Gang Y; Okuno M; Sakurabayashi I
    Rinsho Byori; 1993 Nov; 41(11):1260-4. PubMed ID: 7506803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
    Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
    Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary evaluation of the new tumor marker, CYFRA 21-1, in lung cancer patients.
    Koga H; Eguchi K; Shinkai T; Tamura T; Ohe Y; Oshita F; Saijo N; Kondo H; Oki K; Okura H
    Jpn J Clin Oncol; 1994 Oct; 24(5):263-8. PubMed ID: 7526016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer.
    Chantapet P; Riantawan P; Lebnak P; Getngern P
    J Med Assoc Thai; 2000 Apr; 83(4):383-91. PubMed ID: 10808698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fundamental and clinical evaluation of immunoradiometric assay (IRMA) for serum pancreatic oncofetal antigen (POA)].
    Ohba N; Hashimoto T; Nishibu M; Kashiwaya Y; Kawai K; Matsubara F; Miyazaki I
    Rinsho Byori; 1989 Feb; 37(2):153-8. PubMed ID: 2733181
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer.
    Buccheri G; Ferrigno D
    J Thorac Cardiovasc Surg; 2001 Nov; 122(5):891-9. PubMed ID: 11689793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The evaluation of the newly produced assay kit for the cytokeratin fragment, "ball ELSA CYFRA21-1"].
    Kimura Y; Ata M; Nakamura S; Fujii T; Kawamura T; Tanada S; Hamamoto K
    Kaku Igaku; 1994 Feb; 31(2):199-206. PubMed ID: 7509886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [An attempt for standardization of serum CA19-9 levels, in order to dissolve the gap between three different methods].
    Hayashi K; Hoshino T; Yanai M; Tsuchiya T; Kumasaka K; Kawano K
    Rinsho Byori; 2004 Jun; 52(6):500-5. PubMed ID: 15283162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preparation and evaluation of a time-resolved fluoroimmunoassay kit for CA50 determination].
    Hang JF; Wu YS; Xu WW; Yu WH; Huang Y; Li M
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):189-92. PubMed ID: 17649634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of serum cytokeratin 19 fragment and sialyl-Lewis x in non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Kameyama M; Suehiro S
    Ann Thorac Surg; 2007 Jan; 83(1):216-21. PubMed ID: 17184666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tumor markers in lung cancer].
    Niho S; Shinkai T
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.
    Li CS; Cheng BC; Ge W; Gao JF
    Int J Clin Pract; 2007 Mar; 61(3):444-8. PubMed ID: 17313612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
    Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
    Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for sialyl Tn antigen: (1). Evaluation of assay conditions and normal values. STN Study Group].
    Imura H; Mori T; Ohkura H; Ishii M; Ariyoshi H; Endo J; Kitao M; Takeda I; Kobayashi H; Inoue M
    Gan To Kagaku Ryoho; 1989 Sep; 16(9):3213-9. PubMed ID: 2782915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
    van Dalen A; Kessler AC
    Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum and tissue distribution of a fragment of cytokeratin 19 (cyfra 21-1) in lung cancer patients.
    Quillien V; Ramee MP; Bansard JY; Meritte H; Briens E; Logeais Y; Langanay T; Corbineau H; Dazord L
    Anticancer Res; 1995; 15(6B):2857-63. PubMed ID: 8669879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of CA 19-9 radioimmunoassay].
    Toya D; Takemori Y; Kidani H; Yoneshima M; Hattori N; Sawabu N
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):509-14. PubMed ID: 6584087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interleukin 3 (IL-3) in diagnosis and monitoring of non-small-cell lung cancer].
    Mroczko B; Szmitkowski M; Czygier M
    Przegl Lek; 1999; 56(12):763-6. PubMed ID: 10789186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 21.1 in metastatic disease.
    van Dalen A
    Anticancer Res; 1996; 16(4B):2345-9. PubMed ID: 8694567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.